Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» JNJ-6372
JNJ-6372
J&J’s Experimental Lung Cancer Drug Receives Breakthrough Therapy Designation
BioSpace
Thu, 03/12/20 - 11:03 am
Janssen
JNJ
FDA
JNJ-6372
breakthrough therapy
metastatic non-small cell lung cancer
Janssen gets FDA breakthrough therapy status for JNJ-6372 to treat metastatic NSCLC
Pharmaceutical Business Review
Wed, 03/11/20 - 10:26 am
Janssen
JNJ
FDA
JNJ-6372
metastatic non-small cell lung cancer